UCL CfMR4

View our CfMR interactive map

If you are at UCL and interested in working with the CfMR, please email Michael Duchen


Prof Derek Hausenloy

Photo

Personal Profile

Name: Derek Hausenloy Email: d.hausenloy@ucl.ac.uk
Title: Prof Tel: 0203 447 9894
Department: Hatter Cardiovascular Institute Fax: 0203 447 9505
Position: Professor of Cardiovascular Medicine Address: The Hatter Cardiovascular Institute, University College Lond, 67 Chenies Mews, London, WC1E 6HX
Research Domain: Basic Life Sciences, Biomedical Imaging (Frontier Disciplines), Cardiometabolic Science, Personalised Medicine, Populations & Lifelong Health Web Page: Personal Web Page

Profile

Research Description

1. The mitochondrial permeability transition pore as a target for cardioprotection in both experimental and clinical models of acute ischaemia-reperfusion injury. 2. The role of mitochondrial morphology in cardioprotection (collaboration with Prof Luca Scorrano, Venetian Institute of Molecular Medicine, Padova, Italy). 3. Evaulating long-term benefits of cardioprotection using small animal cardiac MRI and echocardiography (collaboration with Dr Mark Lythgoe). 4. Evaluating cardioprotection and myocardial characterisation in patients presenting with an acute myocardial infarction using cardiac MRI (collaboration with Dr James Moon, Dr Andrew Taylor). 5. Exploring new treatment strategies for reducing myocardial injury and improving clinical outcomes in patients presenting with an acute myocardial infarction and in patients undergoing cardiac surgery.

Research Activities

The role of mitochondria in cardioprotection

Education Description

1. Lecturer of Cardiology and Physiology for BSc Physiology. 2. Clinical teaching to medical students: history and examination techniques.. 3. Organise SSC Cardiology course for 3rd year medical students entitled Cardiology:Bench to bedside. 4. Supervise laboratory and reading projects for BSc students.

UCL Collaborators

Dr Sean Davidson; Prof James Moon; Prof Michael Duchen; Prof Mark Lythgoe

External Collaborators

Publications

    2015

    • Pickard JM, Bøtker HE, Crimi G, Davidson B, Davidson SM, Dutka D, Ferdinandy P, Ganske R, Garcia-Dorado D, Giricz Z, Gourine AV, Heusch G, Kharbanda R, Kleinbongard P, MacAllister R, McIntyre C, Meybohm P, Prunier F, Redington A, Robertson NJ, Suleiman MS, Vanezis A, Walsh S, Yellon DM, Hausenloy DJ (2015). Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop.. Basic Res Cardiol, 110(1), 453 - . doi:10.1007/s00395-014-0453-6

    2014

    • Ong SB, Dongworth R, Cabrera-Fuentes HA, Hausenloy D (2014). The role of the MPTP in conditioning the heart - translatability and mechanism.. Br J Pharmacol, , - . doi:10.1111/bph.13013
    • Beikoghli Kalkhoran S, Hall AR, Whittington H, Davidson SM, Yellon DM, Hausenloy DJ (2014). 4 characterisation of mitochondrial morphology in the adult rodent heart.. Heart, 100 Suppl 1, A2 - A3. doi:10.1136/heartjnl-2013-305297.4
    • Lecour S, Bøtker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JP, Van Laake LW, Yellon DM, Hausenloy DJ (2014). ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies.. Cardiovasc Res, , - . doi:10.1093/cvr/cvu225
    • Ong SB, Hall AR, Dongworth RK, Kalkhoran S, Pyakurel A, Scorrano L, Hausenloy DJ (2014). Akt protects the heart against ischaemia-reperfusion injury by modulating mitochondrial morphology.. Thromb Haemost, 113(1), - . doi:10.1160/TH14-07-0592
    • Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R (2014). Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning.. Pharmacol Rev, 66(4), 1142 - 1174. doi:10.1124/pr.113.008300
    • White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ (2014). Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction.. JACC Cardiovasc Interv, , - . doi:10.1016/j.jcin.2014.05.015
    • Candilio L, Malik A, Ariti C, Barnard M, Di Salvo C, Lawrence D, Hayward M, Yap J, Roberts N, Sheikh A, Kolvekar S, Hausenloy DJ, Yellon DM (2014). Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial.. Heart, , - . doi:10.1136/heartjnl-2014-306178
    • Sluijter JPG, Van Laake LW, Condorelli G, Davidson SM, Engel FB, Ferdinandy P, Hausenloy DJ, Lecour S, Madonna R, Ovize M, Ruiz-Meana M, Schulz R (2014). Novel therapeutic strategies for cardioprotection. Pharmacology and Therapeutics, 144(1), 60 - 70. doi:10.1016/j.pharmthera.2014.05.005
    • Healy DA, Khan WA, Wong CS, Moloney MC, Grace PA, Coffey JC, Dunne C, Walsh SR, Sadat U, Gaunt ME, Chen S, Tehrani S, Hausenloy DJ, Yellon DM, Kramer RS, Zimmerman RF, Lomivorotov VV, Shmyrev VA, Ponomarev DN, Rahman IA, Mascaro JG, Bonser RS, Jeon Y, Hong DM, Wagner R, Thielmann M, Heusch G, Zacharowski K, Meybohm P, Bein B, Tang TY (2014). Remote preconditioning and major clinical complications following adult cardiovascular surgery: Systematic review and meta-analysis. International Journal of Cardiology, 176(1), 20 - 31. doi:10.1016/j.ijcard.2014.06.018
    • Ong SG, Lee WH, Theodorou L, Kodo K, Lim SY, Shukla DH, Briston T, Kiriakidis S, Ashcroft M, Davidson SM, Maxwell PH, Yellon DM, Hausenloy DJ (2014). HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondria permeability transition pore.. Cardiovasc Res, , - . doi:10.1093/cvr/cvu172
    • Dongworth R, Campbell-Washburn A, Roberts T, Yellon D, Lythgoe M, Hausenloy DJ (2014). P645T2-mapping cardiac MRI for in vivo quantification of myocardial area-at-risk.. Cardiovasc Res, 103 Suppl 1, S117 - . doi:10.1093/cvr/cvu098.71
    • Cabrera-Fuentes HA, Ruiz-Meana M, Kostin S, Lecour S, Hausenloy DJ, Garcia-Dorado DJ, Schluter K, Preissner K (2014). P166Extracellular RNA in cardiac ischemia/reperfusion injury: prevention of heart failure and cell damage by RNase1.. Cardiovasc Res, 103 Suppl 1, S29 - . doi:10.1093/cvr/cvu082.103
    • Samangouei P, Elder J, Burke N, Hall A, Hausenloy DJ (2014). P143Targeting the mitochondrial fission proteins, MiD49 and MiD51, as a therapeutic strategy for cardioprotection.. Cardiovasc Res, 103 Suppl 1, S25 - . doi:10.1093/cvr/cvu082.82
    • Hall AR, Dongworth R, Kumar S, Burke N, Yellon D, Hausenloy DJ (2014). P445The differential effects of Sirtuin-3 in cardio-protection.. Cardiovasc Res, 103 Suppl 1, S82 - . doi:10.1093/cvr/cvu091.124
    • Neary MT, Ng KE, Ludtmann MH, Hall AR, Piotrowska I, Ong SB, Hausenloy DJ, Mohun TJ, Abramov AY, Breckenridge RA (2014). Hypoxia signaling controls postnatal changes in cardiac mitochondrial morphology and function.. J Mol Cell Cardiol, , - . doi:10.1016/j.yjmcc.2014.06.013
    • Sluijter JP, Condorelli G, Davidson SM, Engel FB, Ferdinandy P, Hausenloy DJ, Lecour S, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Van Laake LW, Nucleus of the European Society of Cardiology Working Group Cellular Biology of the Heart (2014). Novel therapeutic strategies for cardioprotection.. Pharmacol Ther, , - . doi:10.1016/j.pharmthera.2014.05.005
    • Dongworth RK, Hall AR, Burke N, Hausenloy DJ (2014). Targeting mitochondria for cardioprotection: examining the benefit for patients.. Future Cardiol, 10(2), 255 - 272. doi:10.2217/fca.14.6
    • Hausenloy DJ, Boston-Griffiths E, Yellon DM, Kunst G, Kolvekar S, Chaubey S, John L, Desai J (2014). The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: A randomised controlled clinical trial. Heart, 100(7), 544 - 549. doi:10.1136/heartjnl-2013-304845
    • Van Den Berg TNA, Rongen GA, Riksen NP, Deinum J, Fröhlich GM, Hausenloy DJ (2014). The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacology and Therapeutics, 142(1), 72 - 87. doi:10.1016/j.pharmthera.2013.11.006
    • Van Den Berg TNA, Rongen GA, Riksen NP, Deinum J, Fröhlich GM, Hausenloy DJ (2014). The cardioprotective effects of mineralocorticoid receptor antagonists. Pharmacology and Therapeutics, 142(1), 72 - 87. doi:10.1016/j.pharmthera.2013.11.006
    • Dongworth RK, Mukherjee UA, Hall AR, Astin R, Ong SB, Yao Z, Dyson A, Szabadkai G, Davidson SM, Yellon DM, Hausenloy DJ (2014). DJ-1 protects against cell death following acute cardiac ischemia-reperfusion injury.. Cell Death Dis, 5, e1082 - . doi:10.1038/cddis.2014.41
    • Hausenloy D, Kunst G, Boston-Griffiths E, Kolvekar S, Chaubey S, John L, Desai J, Yellon D (2014). The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial.. Heart, , - . doi:10.1136/heartjnl-2013-304845
    • Cabrera-Fuentes HA, Ruiz-Meana M, Simsekyilmaz S, Kostin S, Inserte J, Saffarzadeh M, Galuska SP, Vijayan V, Barba I, Barreto G, Fischer S, Lochnit G, Ilinskaya ON, Baumgart-Vogt E, Böning A, Lecour S, Hausenloy DJ, Liehn EA, Garcia-Dorado D, Schlüter KD, Preissner KT (2014). RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury.. Thromb Haemost, 112(6), - . doi:10.1160/TH14-08-0703

    2013

    • Siddall HK, Yellon DM, Ong S-B, Mukherjee UA, Burke N, Hall AR, Angelova PR, Ludtmann MHR, Deas E, Davidson SM, Mocanu MM, Hausenloy DJ (2013). Correction: Loss of PINK1 increases the heart's vulnerability to ischemia- reperfusion injury (PLoS ONE). PLoS ONE, 8(6), - . doi:10.1371/annotation/94fd6502-4b2d-409c-8836-66fe6ebc03ab
    • Ong SB, Hall AR, Hausenloy DJ (2013). Mitochondrial dynamics in cardiovascular health and disease.. Antioxid Redox Signal, 19(4), 400 - 414. doi:10.1089/ars.2012.4777
    • Candilio LC, Babu B, Malik AM, Ariti CA, Lawrence DL, Di Salvo CDS, Hayward MH, Yap JY, Yap JY, Sheikh AS, Roberts NR, Kolvekar SK, Hausenloy DJH, Yellon DY (2013). MULTI-LIMB REMOTE ISCHAEMIC PRECONDITIONING REDUCES MYOCARDIAL INJURY IN DIABETIC PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY. doi:10.1136/heartjnl-2013-304019.124
    • Candilio L, Malik A, Ariti C, Barnard M, Wright S, Smith A, Giannaris S, Ashley E, Martin B, Hamilton-Davies C, Cordery R, Hurley R, Bertoja E, Burt C, Di Salvo C, Lawrence D, Hayward M, Yap J, Roberts N, McGregor C, Sheikh A, Kolvekar S, Hausenloy DJ, Yellon DM (2013). THE EFFECTS OF MULTI-LIMB REMOTE ISCHAEMIC PRECONDITIONING IN PATIENTS UNDERGOING CARDIAC BYPASS SURGERY. doi:10.1136/heartjnl-2013-304019.123
    • Akdeniz C, Umman S, Kaplan A, Nisanci Y, Umman B, Buğra Z, Aslanger E, Hausenloy DJ, Yilmaz A, Polat N, Sezer M (2013). Coronary Plaque Composition and Post-PCI Complications in NSTEMI.. JACC Cardiovasc Imaging, 6(12), 1349 - 1350. doi:10.1016/j.jcmg.2013.04.020
    • Hall A, Burke N, Dongworth R, Hausenloy D (2013). Mitochondrial fusion and fission proteins: Novel therapeutic targets for combating cardiovascular disease.. Br J Pharmacol, , - . doi:10.1111/bph.12516
    • van den Berg TN, Rongen GA, Frohlich G, Deinum J, Hausenloy DJ, Riksen NP (2013). The cardioprotective effects of mineralocorticoid receptor antagonists.. Pharmacol Ther, , - . doi:10.1016/j.pharmthera.2013.11.006
    • Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM (2013). Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.. Cardiovasc Diabetol, 12(1), 154 - . doi:10.1186/1475-2840-12-154
    • Tehrani S, Malik A, Hausenloy DJ (2013). Cardiogenic shock and the ICU patient 2C04 3C00. Journal of the Intensive Care Society, 14(3), 235 - 243.
    • Malik A, Candilio L, Hausenloy DJ (2013). RE: Discharging patients from ICU.
    • Hirsch E, Hilfiker-Kleiner D, Balligand JL, Tarone G, de Windt L, Bauersachs J, Ferdinandy P, Davidson S, Hausenloy D, Schulz R (2013). Interaction of the heart and its close and distant neighbours Report of the Meeting of the ESC Working Groups Myocardial Function and Cellular Biology.. Cardiovasc Res, , - . doi:10.1093/cvr/cvt179
    • Rees PSC, Davidson SM, Harding SE, McGregor C, Elliot PM, Yellon DM, Hausenloy DJ (2013). The Mitochondrial Permeability Transition Pore as a Target for Cardioprotection in Hypertrophic Cardiomyopathy. CARDIOVASCULAR DRUGS AND THERAPY, 27(3), 235 - 237. doi:10.1007/s10557-013-6447-z
    • Malik A, Candilio L, Hausenloy DJ (2013). Atrial fibrillation in the intensive care setting. Journal of the Intensive Care Society, 14(2), 141 - 149.
    • Whittington HJ, Harding I, Stephenson CI, Bell R, Hausenloy DJ, Mocanu MM, Yellon DM (2013). Cardioprotection in the aging, diabetic heart: the loss of protective Akt signaling.. Cardiovasc Res, , - . doi:10.1093/cvr/cvt140
    • Siddall HK, Yellon DM, Ong SB, Mukherjee UA, Burke N, Hall AR, Angelova PR, Ludtmann MH, Deas E, Davidson SM, Mocanu MM, Hausenloy DJ (2013). Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury.. PLoS One, 8(4), e62400 - . doi:10.1371/journal.pone.0062400
    • White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC (2013). T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique.. JACC Cardiovasc Imaging, 6(9), 955 - 962. doi:10.1016/j.jcmg.2013.01.011
    • Candilio L, Malik A, Hausenloy DJ (2013). Protection of organs other than the heart by remote ischemic conditioning. Journal of Cardiovascular Medicine, 14(3), 193 - 205. doi:10.2459/JCM.0b013e328359dd7b
    • Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ (2013). Myocardial reperfusion injury: looking beyond primary PCI.. Eur Heart J, 34(23), 1714 - 1722. doi:10.1093/eurheartj/eht090
    • Tehrani S, Laing C, Yellon DM, Hausenloy DJ (2013). Contrast-induced acute kidney injury following PCI.. Eur J Clin Invest, 43(5), 483 - 490. doi:10.1111/eci.12061
    • Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM (2013). Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon. Cardiovascular Drugs and Therapy, 27(1), 5 - 16. doi:10.1007/s10557-012-6425-x
    • Hausenloy DJ, Erik Bøtker H, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M (2013). Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.. Cardiovasc Res, 98(1), 7 - 27. doi:10.1093/cvr/cvt004
    • Hausenloy DJ, Yellon DM (2013). Myocardial ischemia-reperfusion injury: a neglected therapeutic target.. J Clin Invest, 123(1), 92 - 100. doi:10.1172/JCI62874
    • Hausenloy DJ (2013). Cardioprotection techniques: preconditioning, postconditioning and remote conditioning (basic science).. Curr Pharm Des, 19(25), 4544 - 4563.
    • Hausenloy DJ, Wynne AM, Mocanu MM, Yellon DM (2013). Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.. J Cardiovasc Pharmacol Ther, 18(3), 263 - 269. doi:10.1177/1074248412468945
    • Dongworth RK, Campbell-Washburn AE, Roberts T, Yellon DM, Lythgoe MF, Hausenloy DJ (2013). T2-MAPPING CARDIAC MAGNETIC RESONANCE IMAGING FOR ASSESSING AREA-AT-RISK IN A MURINE MODEL OF MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY. doi:10.1136/heartjnl-2013-304019.225

    2012

    • Hausenloy DJ (2012). Management of Myocardial Reperfusion Injury.
    • Flett AS, Sado DM, Quarta G, Mirabel M, Pellerin D, Herrey AS, Hausenloy DJ, Ariti C, Yap J, Kolvekar S, Taylor AM, Moon JC (2012). Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study.. Eur Heart J Cardiovasc Imaging, 13(10), 819 - 826. doi:10.1093/ehjci/jes102
    • Kelly-Laubscher R, Burger G, Davies N, Engelbrecht A-M, Sliwa K, Lecour S, Strijdom H, Hausenloy D (2012). 2nd South Africa-United Kingdom cardiovascular workshop Highlighting cardiovascular research in South Africa. CARDIOVASCULAR JOURNAL OF AFRICA, 23(10), 572 - 573.
    • White SK, Hausenloy DJ, Moon JC (2012). Imaging the myocardial microcirculation post-myocardial infarction. Current Heart Failure Reports, 9(4), 282 - 292. doi:10.1007/s11897-012-0111-y
    • Riksen NP, Hausenloy DJ (2012). Limitation of myocardial ischemia-reperfusion injury in clinical practice: new hopes and disappointments.. Curr Opin Lipidol, 23(6), 588 - 590. doi:10.1097/MOL.0b013e32835a0e0a
    • Meier P, Froehlich GM, Hausenloy DJ, Yellon DM (2012). Predicting peri-procedural myocardial infarction during PCI. Heart, 98(20), 1471 - 1472. doi:10.1136/heartjnl-2012-302783
    • Ong S-G, Hausenloy DJ (2012). Hypoxia-inducible factor as a therapeutic target for cardioprotection. Pharmacology and Therapeutics, 136(1), 69 - 81. doi:10.1016/j.pharmthera.2012.07.005
    • Hausenloy DJ, Yellon DM, Maddock HL, Baxter GF (2012). Paradigm shifts in cardioprotection research: The importance of the MPTP as a therapeutic target. Cardiovascular Research, 96(2), 160 - 164. doi:10.1093/cvr/cvs174
    • Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, Lachmann RH, Murphy E, Mehta A, Hughes DA, McKenna WJ, Taylor AM, Hausenloy DJ, Hawkins PN, Elliott PM, Moon JC (2012). Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease.. Heart, 98(19), 1436 - 1441. doi:10.1136/heartjnl-2012-302346
    • Bell R, Beeuwkes R, Bøtker HE, Davidson S, Downey J, Garcia-Dorado D, Hausenloy DJ, Heusch G, Ibanez B, Kitakaze M, Lecour S, Mentzer R, Miura T, Opie L, Ovize M, Ruiz-Meana M, Schulz R, Shannon R, Walker M, Vinten-Johansen J, Yellon D (2012). Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop.. Basic Res Cardiol, 107(6), 300 - . doi:10.1007/s00395-012-0300-6
    • Hausenloy DJ, Boston-Griffiths EA, Yellon DM (2012). Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent.. Br J Pharmacol, 165(5), 1235 - 1245. doi:10.1111/j.1476-5381.2011.01700.x
    • Hausenloy DJ, Yellon DM (2012). Taking lizard saliva to heart.. Eur Heart J, 33(12), 1426 - 1430. doi:10.1093/eurheartj/ehr382
    • Kunuthur SP, Mocanu MM, Hemmings BA, Hausenloy DJ, Yellon DM (2012). The Akt1 isoform is an essential mediator of ischaemic preconditioning.. J Cell Mol Med, 16(8), 1739 - 1749. doi:10.1111/j.1582-4934.2011.01491.x
    • Hausenloy DJ, Candilio L, Laing C, Kunst G, Pepper J, Kolvekar S, Evans R, Robertson S, Knight R, Ariti C, Clayton T, Yellon DM, ERICCA Trial Investigators (2012). Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial.. Clin Res Cardiol, 101(5), 339 - 348. doi:10.1007/s00392-011-0397-x
    • Hausenloy DJ, Iliodromitis EK, Andreadou I, Papalois A, Gritsopoulos G, Anastasiou-Nana M, Kremastinos DT, Yellon DM (2012). Investigating the signal transduction pathways underlying remote ischemic conditioning in the porcine heart.. Cardiovasc Drugs Ther, 26(2), 87 - 93. doi:10.1007/s10557-011-6364-y
    • Sharma V, Candilio L, Hausenloy DJ (2012). Infective endocarditis: An intensive care perspective. Trends in Anaesthesia and Critical Care, 2(1), 36 - 41. doi:10.1016/j.tacc.2011.11.004
    • Hausenloy DJ (2012). Magnitude and relevance of reperfusion injury. Heart and Metabolism, (54), 5 - 8.
    • Lim SY, Hausenloy DJ (2012). Remote ischemic conditioning: from bench to bedside.. Front Physiol, 3, 27 - . doi:10.3389/fphys.2012.00027
    • Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ (2012). The diabetic heart: Too sweet for its own good?. Cardiology Research and Practice, 1(1), - . doi:10.1155/2012/845698
    • Sado D, Flett A, White SK, Banypersad SM, Maestrini V, Mehta A, Hawkins PN, Hausenloy DJ, Elliott P, Moon J (2012). Interstitial expansion in health and disease - an equilibrium contrast CMR study.. doi:10.1186/1532-429X-14-S1-O23
    • Treibel TA, White SK, Sado D, Hasleton J, Flett A, Herrey AS, Hausenloy DJ, Moon J (2012). Not all LGE is the same. Scar contrast volume of distribution is lower in HCM than in infarction.. doi:10.1186/1532-429X-14-S1-O95
    • Dongworth R, Yellon DM, Hausenloy DJ (2012). Cyclophilin-D ablation offers long-term protection against lethal myocardial reperfusion injury.
    • Mukherjee U, Ong SB, Davidson SM, Szabadkai G, Yellon DM, Hausenloy DJ (2012). Mitochondrial DJ-1 as a target for cardioprotection.
    • Sirohi R, Roberts N, Lawrence D, Sheikh A, Kolvekar S, Yap J, Arend M, Walkinshaw G, Hausenloy DJ, Yellon DM (2012). Stabilisation of hypoxia inducible factor at reperfusion protects human atrial trabeculae against ischaemia-reperfusion injury.
    • Hausenloy DJ, Boston-Griffiths E, Yellon DM (2012). Cardioprotection during cardiac surgery.. Cardiovasc Res, 94(2), 253 - 265. doi:10.1093/cvr/cvs131
    • Hall AR, Hausenloy DJ (2012). The shape of things to come: mitochondrial fusion and fission in the adult heart.. Cardiovasc Res, 94(3), 391 - 392. doi:10.1093/cvr/cvs150
    • Hausenloy DJ, Yellon DM (2012). "Conditional Conditioning" in cardiac bypass surgery.. Basic Res Cardiol, 107(3), 258 - . doi:10.1007/s00395-012-0258-4
    • Hausenloy DJ (2012). Conditioning the heart to prevent myocardial reperfusion injury during PPCI.. Europ Heart J Acute Cardiovasc Care, 1(1), 13 - 32. doi:10.1177/2048872612438805

    2011

    • Flett AS, Sado DM, Quarta G, Huttin O, Hausenloy DJ, Banypersad SM, Pellerin D, Mcgregor C, Taylor AM, Moon JC (2011). Aortic stenosis is as much a disease of the myocardium as of the valve - the role of diffuse myocardial fibrosis as measured by EQ-CMR. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 183, 777 - 777.
    • Whittington HJ, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM (2011). 39 Endogenous protection against myocardial ischaemia-reperfusion injury in the diabetic heart.. doi:10.1136/heartjnl-2011-301156.39
    • Hausenloy DJ, Lecour S, Yellon DM (2011). Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin.. Antioxid Redox Signal, 14(5), 893 - 907. doi:10.1089/ars.2010.3360
    • Babu GG, Walker JM, Yellon DM, Hausenloy DJ (2011). Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.. Eur Heart J, 32(1), 23 - 31. doi:10.1093/eurheartj/ehq393
    • Lim SY, Hausenloy DJ, Arjun S, Price AN, Davidson SM, Lythgoe MF, Yellon DM (2011). Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure.. J Cell Mol Med, 15(11), 2443 - 2451. doi:10.1111/j.1582-4934.2010.01235.x
    • Smith CC, Lim SY, Wynne AM, Sivaraman V, Davidson SM, Mocanu MM, Hausenloy DJ, Yellon DM (2011). Failure of the adipocytokine, resistin, to protect the heart from ischemia-reperfusion injury.. J Cardiovasc Pharmacol Ther, 16(1), 63 - 71. doi:10.1177/1074248410382232
    • Hausenloy DJ (2011). Funding: International society for heart research, European section/servier research fellowship: "Pivotal in establishing my independent career in cardiovascular research". Circulation, 124(1), - . doi:10.1161/CIR.0b013e3182137c60
    • Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC (2011). Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance.. JACC Cardiovasc Imaging, 4(2), 150 - 156. doi:10.1016/j.jcmg.2010.11.015
    • Quarta G, Holdright DR, Plant GT, Harkness A, Hausenloy D, Hyare H, Moon JC (2011). Cardiovascular magnetic resonance in cardiac sarcoidosis with MR conditional pacemaker in situ.. J Cardiovasc Magn Reson, 13, 26 - . doi:10.1186/1532-429X-13-26
    • Hausenloy DJ, Yellon DM (2011). The therapeutic potential of ischemic conditioning: an update.. Nat Rev Cardiol, 8(11), 619 - 629. doi:10.1038/nrcardio.2011.85
    • Ludman AJ, Hausenloy DJ, Babu G, Hasleton J, Venugopal V, Boston-Griffiths E, Yap J, Lawrence D, Hayward M, Kolvekar S, Bognolo G, Rees P, Yellon DM (2011). Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial.. doi:10.1007/s00395-011-0209-5
    • Candilio L, Hausenloy DJ, Yellon DM (2011). Remote ischemic conditioning: a clinical trial's update.. J Cardiovasc Pharmacol Ther, 16(3-4), 304 - 312. doi:10.1177/1074248411411711
    • Price AN, Cheung KK, Lim SY, Yellon DM, Hausenloy DJ, Lythgoe MF (2011). Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4T.. J Cardiovasc Magn Reson, 13, 44 - . doi:10.1186/1532-429X-13-44
    • Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E, Venugopal V, Walker M, Holdright D, Swanton H, Crake T, Brull D, Moon JC, Puranik R, Muthurangu V, Taylor A, Hausenloy DJ (2011). Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.. Heart, 97(19), 1560 - 1565. doi:10.1136/hrt.2011.223867
    • Rees PSC, Hausenloy DJ, Yellon DM (2011). Atorvastatin, Administered at the Onset of Reperfusion, Protects Human Myocardium Against Lethal Reperfusion Injury by Activation of the RISK pathway.
    • Rees PSC, Davidson SM, Harding SE, Elliott PM, Hausenloy DJ, Yellon DM (2011). The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy.
    • Dongworth R, Yellon DM, Hausenloy DJ (2011). 36 Cyclophilin-D ablation offers long-term protection against acute myocardial ischaemia-reperfusion injury.. doi:10.1136/heartjnl-2011-301156.36
    • Mukherjee UA, Ong SB, Davidson SM, Yellon DM, Hausenloy DJ (2011). 37 A novel role for DJ-1 in cardioprotection.. doi:10.1136/heartjnl-2011-301156.37
    • Flett AS, Sado DM, Quarta G, Huttin O, Hausenloy DJ, Banypersad SM, Pellerin D, Mcgregor C, Taylor AM, Moon JC (2011). Aortic stenosis is as much a disease of the myocardium as of the valve - the role of diffuse myocardial fibrosis as measured by EQ-CMR. EUROPEAN HEART JOURNAL, 32, 777 - 777.

    2010

    • Sivaraman V, Hausenloy DJ, Wynne AM, Yellon DM (2010). Preconditioning the diabetic human myocardium.. J Cell Mol Med, 14(6B), 1740 - 1746. doi:10.1111/j.1582-4934.2009.00796.x
    • Venugopal V, Laing CM, Ludman A, Yellon DM, Hausenloy D (2010). Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials.. Am J Kidney Dis, 56(6), 1043 - 1049. doi:10.1053/j.ajkd.2010.07.014
    • Hausenloy DJ, Ruiz-Meana M (2010). Editorial: Not just the powerhouse of the cell: Emerging roles for mitochondria in the heart. Cardiovascular Research, 88(1), 5 - 6. doi:10.1093/cvr/cvq259
    • Flett AS, Hasleton JM, Quarta G, Hausenloy D, Muthurangu V, Moon JC (2010). The Full Width Half Maximum technique is superior for LGE quantification regardless of its aetiology. Journal of Cardiovascular Magnetic Resonance, 12(SUPPL. 1), - . doi:10.1186/1532-429X-12-S1-O41
    • Hausenloy DJ, Lim SY, Ong SG, Davidson SM, Yellon DM (2010). Mitochondrial cyclophilin-D as a critical mediator of ischaemic preconditioning.. Cardiovasc Res, 88(1), 67 - 74. doi:10.1093/cvr/cvq113
    • Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ (2010). Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury.. Circulation, 121(18), 2012 - 2022. doi:10.1161/CIRCULATIONAHA.109.906610
    • Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R, Working Group of Cellular Biology of Heart of European Society of Cardiology (2010). Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.. Cardiovasc Res, 87(3), 406 - 423. doi:10.1093/cvr/cvq129
    • Lim SY, Yellon DM, Hausenloy DJ (2010). The neural and humoral pathways in remote limb ischemic preconditioning.. Basic Res Cardiol, 105(5), 651 - 655. doi:10.1007/s00395-010-0099-y
    • Hausenloy DJ, Yellon DM (2010). The second window of preconditioning (SWOP) where are we now?. Cardiovasc Drugs Ther, 24(3), 235 - 254. doi:10.1007/s10557-010-6237-9
    • Rees PSC, Babu GG, Boston-Griffiths EA, Bognolo G, Hayward M, Kolvekar S, Lawrence D, Yap J, Hausenloy DJ, Yellon DM (2010). ATORVASTATIN PROTECTS HUMAN MYOCARDIUM FROM LETHAL ISCHAEMIA-REPERFUSION INJURY BY ACTIVATING THE RISK PATHWAY. doi:10.1136/hrt.2010.195941.14
    • Hausenloy DJ, Yellon DM (2010). Cell membrane repair as a mechanism for ischemic preconditioning?. Circulation, 121(23), 2547 - 2549. doi:10.1161/CIRCULATIONAHA.110.958462
    • Ludman AJ, Hasleton J, Babu G, Boston-Griffiths E, Venugopal V, Moon JC, Muthurangu V, Taylor AM, Puranik R, Yellon DM, Hausenloy DJ (2010). DETRIMENTAL EFFECTS OF ERYTHROPOIETIN AS AN ADJUNCT TO PPCI: A RANDOMISED CONTROLLED TRIAL IN ACUTE MI USING CARDIAC MRI. doi:10.1136/hrt.2010.195958.12
    • Lim SY, Arjun S, Price AN, Davidson SM, Lythgoe MF, Hausenloy DJ, Yellon DM (2010). MITOCHONDRIAL CYCLOPHILIN-D AS A THERAPEUTIC TARGET FOR POST-MYOCARDIAL INFARCTION HEART FAILURE. doi:10.1136/hrt.2010.195941.15
    • Ong SB, Arjun S, Lim SY, Davidson SM, Yellon DM, Hausenloy DJ (2010). MODULATING MITOCHONDRIAL DYNAMICS AS A NOVEL CARDIOPROTECTIVE STRATEGY. doi:10.1136/hrt.2010.195941.13
    • Lim SY, Yellon DM, Hausenloy DJ (2010). THE INTERACTION BETWEEN THE HUMOURAL AND NEURAL PATHWAYS UNDERLYING REMOTE ISCHAEMIC PRECONDITIONING. doi:10.1136/hrt.2010.195941.18
    • Sharma V, Rao GG, Jackson G, Hausenloy D (2010). Infective Endocarditis in the UK: A District General Hospital Experience.
    • Ong SB, Hausenloy DJ (2010). Mitochondrial morphology and cardiovascular disease.. Cardiovasc Res, 88(1), 16 - 29. doi:10.1093/cvr/cvq237
    • Hausenloy DJ, Opie L, Yellon DM (2010). Dissociating HDL cholesterol from cardiovascular risk.. Lancet, 376(9738), 305 - 306. doi:10.1016/S0140-6736(10)61021-5
    • Smith CC, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, Davidson SM, Hausenloy DJ, Yellon DM (2010). Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore.. Am J Physiol Heart Circ Physiol, 299(4), H1265 - H1270. doi:10.1152/ajpheart.00092.2010
    • Hausenloy DJ, Ruiz-Meana M (2010). Not just the powerhouse of the cell: emerging roles for mitochondria in the heart.. Cardiovasc Res, 88(1), 5 - 6. doi:10.1093/cvr/cvq259
    • Hausenloy DJ, Wynne AM, Theodorou L, Mocanu M, Yellon DM (2010). Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner.
    • Ludman AJ, Hasleton JM, Venugopal V, Babu G, Moon JC, Muthurangu V, Taylor A, Puranik R, Yellon DM, Hausenloy DJ (2010). The effect of erythropoietin as an adjunct to PPCI: a randomised controlled trial.
    • Ludman AJ, Hausenloy DJ, Venugopal V, Babu G, Boston-Griffiths E, Lawrence D, Yap J, Hayward M, Bognolo G, Yellon DM (2010). The effect of high-dose atorvastatin on a background of standard-dose chronic statin therapy in patients undergoing cardiac surgery.
    • Rees PSC, Davidson SM, Harding SE, Elliott PM, Yellon DM, Hausenloy DJ (2010). The mitochondrial permeability transition pore is a functional target for cardioprotection in human hypertrophic cardiomyopathy.
    • Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM (2010). Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.. Basic Res Cardiol, 105(6), 677 - 686. doi:10.1007/s00395-010-0121-4
    • Ludman AJ, Yellon DM, Hausenloy DJ (2010). Cardiac preconditioning for ischaemia: lost in translation.. Dis Model Mech, 3(1-2), 35 - 38. doi:10.1242/dmm.003855

    2009

    • Venugopal V, Hausenloy DJ, Ludman A, Liang C, Yellon DM (2009). Remote ischaemic preconditioning reduces renal injury in patients undergoing coronary artery bypass graft surgery.
    • Hausenloy DJ, Ong SB, Yellon DM (2009). The mitochondrial permeability transition pore as a target for preconditioning and postconditioning.. Basic Res Cardiol, 104(2), 189 - 202. doi:10.1007/s00395-009-0010-x
    • Ludman AJ, Hausenloy DJ, Venugopal V, Yellon DM (2009). Premature meta-analysis of remote ischemic preconditioning.. doi:10.1016/j.amjcard.2008.12.024
    • Hausenloy DJ (2009). Drug discovery possibilities from visfatin cardioprotection?. Curr Opin Pharmacol, 9(2), 202 - 207. doi:10.1016/j.coph.2008.10.005
    • Hausenloy DJ (2009). Signalling pathways in ischaemic postconditioning.. Thromb Haemost, 101(4), 626 - 634.
    • Ludman A, Venugopal V, Yellon DM, Hausenloy DJ (2009). Statins and cardioprotection--more than just lipid lowering?. Pharmacol Ther, 122(1), 30 - 43. doi:10.1016/j.pharmthera.2009.01.002
    • Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Gonçalves L, Providência L, Rongen GA, Smits P, Mocanu MM, Yellon DM (2009). Metformin prevents myocardial reperfusion injury by activating the adenosine receptor.. J Cardiovasc Pharmacol, 53(5), 373 - 378. doi:10.1097/FJC.0b013e31819fd4e7
    • Sivaraman V, Hausenloy DJ, Kolvekar S, Hayward M, Yap J, Lawrence D, Di Salvo C, Yellon DM (2009). The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium.. J Mol Cell Cardiol, 46(5), 758 - 764. doi:10.1016/j.yjmcc.2009.02.013
    • Lim S, Ong SG, Shukla DH, Maxwell P, Hausenloy DJ, Yellon DM (2009). ACTIVATING HYPOXIA INDUCIBLE FACTOR IN THE HEART BY GENETIC INACTIVATION OF VON HIPPEL LINDAU PROTEIN REDUCES MYOCARDIAL INFARCT SIZE.
    • Venugopal V, Ludman A, Yellon DM, Hausenloy DJ (2009). 'Conditioning' the heart during surgery.. Eur J Cardiothorac Surg, 35(6), 977 - 987. doi:10.1016/j.ejcts.2009.02.014
    • Hausenloy DJ (2009). Contrave (TM): novel treatment for obesity. CLIN LIPIDOL, 4(3), 279 - 285. doi:10.2217/CLP.09.12
    • Rees PSC, Ludman AJ, Teoh KL, Bognolo G, Kolvekar S, Yap J, Lawrence D, Hayward M, Hausenloy DJ, Yellon DM (2009). HIGH-DOSE ORAL ATORVASTATIN PRETREATMENT OF PATIENTS UNDERGOING CARDIAC SURGERY PROTECTS ATRIAL MUSCLE AGAINST SIMULATED ISCHAEMIA-REPERFUSION INJURY.
    • Ong SB, Davidson S, Yellon DM, Hausenloy DJ (2009). MITOCHONDRIAL FUSION BY GENETIC OR PHARMACOLOGICAL MANIPULATION PROTECTS AGAINST ISCHAEMIA-REPERFUSION INJURY.
    • Hausenloy DJ, Yellon DM (2009). Preconditioning and postconditioning: underlying mechanisms and clinical application.. Atherosclerosis, 204(2), 334 - 341. doi:10.1016/j.atherosclerosis.2008.10.029
    • Iliodromitis EK, Papalois A, Gritsopoulos G, Kremastinos DT, Yellon DM, Hausenloy DJ (2009). REMOTE ISCHAEMIC PRECONDITIONING AND POSTCONDITIONING AND THE REPERFUSION INJURY SALVAGE KINASE PATHWAY.
    • Davidson SM, Lim SY, Yellon DM, Hausenloy DJ (2009). THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE AS A MEDIATOR OF ISCHAEMIC PRECONDITIONING.
    • Hausenloy DJ, Yellon DM (2009). Cardioprotective growth factors.. Cardiovasc Res, 83(2), 179 - 194. doi:10.1093/cvr/cvp062
    • Hausenloy DJ, Yellon DM (2009). Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.. Curr Opin Cardiol, 24(5), 473 - 482. doi:10.1097/HCO.0b013e32832ebfe7
    • Riksen NP, Wynne A, Yellon DM, Hausenloy DJ (2009). Ischaemic preconditioning and postconditioning do not affect adenosine A(1) and A (2A) receptor sensitivity.. Cardiovasc Drugs Ther, 23(5), 415 - 417. doi:10.1007/s10557-009-6196-1
    • Hausenloy D, Yellon D (2009). Cardioprotection.
    • Venugopal V, Ludman A, Yellon DM, Hausenloy DJ (2009). Corrigendum to "'Conditioning' the heart during surgery" [Eur. J. Cardiothorac. Surg. 35 (6) (2009) 977-987] (DOI:10.1016/j.ejcts.2009.02.014). doi:10.1016/j.ejcts.2009.06.012
    • Hausenloy DJ, Yellon DM (2009). Myocardial protection: is primary PCI enough?. Nature Clinical Practice Cardiovascular Medicine, 6(1), 12 - 13. doi:10.1038/ncpcardio1371
    • Hausenloy DJ (2009). Urinary trypsin inhibition: cardioprotection via the reperfusion injury salvage kinase pathway.. Cardiology, 114(4), 261 - 263. doi:10.1159/000234320
    • Venugopal V, Ludman A, Yellon DM, Hausenloy DJ (2009). Reply to Landoni et al.. Eur J Cardiothorac Surg, , - . doi:10.1016/j.ejcts.2009.09.037
    • Hausenloy DJ, Arhi C, Chandra N, Franzen-McManus AC, Meyer A, Sutton R (2009). Blood pressure oscillations during tilt testing as a predictive marker of vasovagal syncope.. Europace, 11(12), 1696 - 1701. doi:10.1093/europace/eup338

    2008

    • Hausenloy DB, G Davidson SC, R Mocanu MY, D (2008). Metformin given at time of reperfusion reduces myocardial infarct size through the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
    • Venugopal V, Ludman A, Hausenloy DJ, Yellon DM (2008). Transient limb ischaemia reduces myocardial injury in patients undergoing cardiac surgery using cardioplegia: a randomised controlled study. EUROPEAN HEART JOURNAL, 29, 111 - 111.
    • Hausenloy DJW, A Mocanu MMY, D M (2008). The metabolic syndrome raises the threshold for cardioprotection.
    • Hausenloy DJ, Pagano D, Keogh B (2008). Aprotinin-still courting controversy.. The Lancet, 371(9611), 449 - 450.
    • Ludman A, Hausenloy DJ, Venugopal V, Yellon DM (2008). Can high-dose atorvastatin provide cardioprotection during coronary artery bypass surgery?. doi:10.1016/j.yjmcc.2008.02.044
    • Hausenloy DJ, Davidson S, Wynne A, Cipolat S, Yellon DM, Scorrano L (2008). Over-expression of the cardioprotective kinase Akt modulates mitochondrial morphology. doi:10.1016/j.yjmcc.2008.02.037
    • Sivaraman V, Hausenloy DJ, Yellon DM (2008). Protein kinase C delta and epsilon isoforms have divergent roles in simulated ischaemia-reperfusion injury in human atrial muscle. doi:10.1016/j.yjmcc.2008.02.051
    • Venugopal V, Ludman A, Hausenloy DJ, Yellon DM (2008). Remote ischaemic preconditioning confers cardioprotection over and above cardioplegia during cardiac surgery. doi:10.1016/j.yjmcc.2008.02.147
    • Sivaraman V, Hausenloy DJ, Yellon DM (2008). The human diabetic myocardium has a higher threshold for protection against simulated ischaemia-reperfusion injury. doi:10.1016/j.yjmcc.2008.02.050
    • Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ (2008). The novel adipocytokine visfatin exerts direct cardioprotective effects. Journal of Cellular and Molecular Medicine, 12(4), 1395 - 1403. doi:10.1111/j.1582-4934.2008.00332.x
    • Riksen NP, Hausenloy DJ, Yellon DM (2008). Erythropoietin: ready for prime-time cardioprotection. Trends in Pharmacological Sciences, 29(5), 258 - 267. doi:10.1016/j.tips.2008.02.002
    • Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM (2008). Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Research in Cardiology, 103(3), 274 - 284. doi:10.1007/s00395-007-0691-y
    • Hausenloy DJ, Yellon DM (2008). Preconditioning and postconditioning: new strategies for cardioprotection.. Diabetes Obes Metab, 10(6), 451 - 459. doi:10.1111/j.1463-1326.2007.00762.x
    • Hausenloy DJ, Yellon DM (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart, 94(6), 706 - 714. doi:10.1136/hrt.2007.125401
    • Sivaraman V, Hausenloy DJ, Yellon DM (2008). The delta and epsilon isoforms of protein kinase C have opposing actions in human atrial muscle during simulated ischaemia-reperfusion injury.
    • Hausenloy DJ, Yellon DM (2008). Invited editorial: Time to take reperfusion injury seriously?. New England Journal of Medicine, 359(5), 518 - 520.
    • Hausenloy DJ, Yellon DM (2008). Time to take myocardial reperfusion injury seriously.. N Engl J Med, 359(5), 518 - 520. doi:10.1056/NEJMe0803746
    • Hausenloy DJ, Yellon D, M (2008). Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovascular Research, 79(3), 377 - 386. doi:10.1093/cvr/cvn114
    • Riksen NP, Hausenloy DJ, Yellon DM (2008). Wake Up and Smell the Coffee: Yet Another No Go for Cardiac Patients? : Editorial to "Caffeinated Coffee Blunts the Myocardial Protective Effects of Statins Against Ischemia-reperfusion Injury in the Rat" by Ye et al.. Cardiovascular Drugs and Therapy, 22(4), 257 - 259. doi:10.1007/s10557-008-6108-9
    • Hausenloy DJ, Yellon DM (2008). Clinical translation of cardioprotective strategies : report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection.. Basic Res Cardiol, 103(5), 493 - 500. doi:10.1007/s00395-008-0736-x
    • Sivaraman V, Hausenloy DJ, Yellon DM (2008). Diabetes raises the threshold for protection in the human muscle subjected to simulated ischaemia-reperfusion injury.
    • Hausenloy DJ, Yellon DM (2008). GLP-1 therapy: beyond glucose control.. Circ Heart Fail, 1(3), 147 - 149. doi:10.1161/CIRCHEARTFAILURE.108.810887
    • Hausenloy DJ, Yellon DM (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.. Postgraduate Medical Journal, 84(997), 590 - 598.
    • Hausenloy DJ (2008). Treatment Strategies for Preventing Lethal Reperfusion Injury. In Mehta S (Ed.), Textbook of Stemi Interventions (pp. - ). : .
    • Hausenloy DJ (2008). Temporary Pacing. In Waldmann C, Soni N, Rhodes A (Ed.), (pp. - ). : Oxford University Press.

    2007

    • Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, MacAllister RJ, Bamard M, Grundy E, Ashley E, Kolvekar S, Hayward M, Keogh B, Yellon DM (2007). Remote ischemic preconditioning using transient arm ischemia reduces myocardial injury during cardiac surgery.
    • Hausenloy DJ, Cipolat S, Yellon DM, Scorrano L (2007). The cardioprotective kinase, Akt, modulates mitochondrial dynamics.
    • Hausenloy DJ, Yellon DM (2007). Preconditioning and postconditioning: united at reperfusion. Pharmacology and Therapeutics, 116(2), 173 - 191. doi:10.1016/j.pharmthera.2007.06.005
    • Mwamure PK, Hausenloy D, Yap J (2007). Infective endocarditis.. East African Medical Journal, 84(12), 603 - .
    • Hausenloy DJ, Yellon DM (2007). Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Failure Reviews, 12(3-4), 217 - 234.
    • Yellon DM, Hausenloy DJ (2007). Myocardial reperfusion injury - Reply.
    • Hausenloy DJ, Venugopal V, Yellon DM (2007). Remote ischaemic preconditioning - Reply.
    • Hausenloy DJ, Yellon DM (2007). 'Conditioning' the heart. Practical Cardiovascular Risk Management, 5(2), 6 - 8.
    • Hausenloy DW, A Mocanu MY, D (2007). Glimepiride treatment facilitates the protective effect of ischaemic preconditioning in the diabetic heart.
    • Hausenloy DJ, Smith CCT, Yellon DM (2007). Protecting the diabetic ischemic heart. In (Ed.), (pp. - ). : University of Cape Town Press.
    • Hausenloy DJ, Yellon DM (2007). Protecting the heart by postconditioning. British Journal of Cardiology, 14(3), 129 - 130.
    • Yellon DM, Hausenloy DJ (2007). The authors reply [17].
    • Hausenloy DJ, Lim SY, Paramanathan AJ, Davidson SM, Yellon DM (2007). Cardioprotective actions of the novel adipocytokine visfatin. doi:10.1016/j.yjmcc.2007.03.654
    • Wynne A, Hausenloy DJ, Mocanu NM, Yellon DM (2007). Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart. doi:10.1016/j.yjmcc.2007.03.543
    • Mudalagiri N, Hausenloy D, Yellon D (2007). Hypoxic and pharmacolgical postconditioning protects the human heart by activating phosphatidylinositol-3-kinase.
    • Hausenloy DJ, Bhamra GS, Davidson SM, Carr R, Mocanu MM, Yellon DM (2007). Metformin cardioprotects the diabetic heart by inhibiting mPTP opening via the risk pathway. doi:10.1016/j.yjmcc.2007.03.655
    • Lim SY, Davidson SM, Hausenloy DJ, Yellon DM (2007). Preconditioning and postconditioning: The essential role of the mitochondrial permeability transition pore. doi:10.1016/j.yjmcc.2007.03.524
    • Shiang-Yong L, Hausenloy D, Davidson S, Yellon D (2007). Preconditioning and postconditioning: The mitochondrial permeablity transition pore as the common end-effector.
    • Mwamure P, Hausenloy D, Harris J, Barnard M, Grundy E, Ashley E, Di Salvo C, Vichare S, Kolvekar S, Hayward M, Keogh B, MacAllister R, Yellon D (2007). Remote ischaemic preconditioning protects the heart at time of CABG surgery.
    • Wynne AM, Hausenloy D (2007). Reperfusion signaling in preconditioned hearts: Role for Pkc, the Mkatp channel, oxidative stress and transient acidosis. doi:10.1016/j.yjmcc.2007.03.531
    • Hausenloy D, Shiang-Yong L, Paramanathan A, Davidson S, Smith C, Yellon D (2007). The adipocytokine, visfatin, reduces myocardial infarct size, when given at time of reperfusion, by inhibiting the mitochondrial permeability transition pore.
    • Hausenloy DJ, Yellon DM (2007). The evolving story of "conditioning" to protect against acute myocardial ischaemia-reperfusion injury. Heart, 93(6), 649 - 651. doi:10.1136/hrt.2007.118828
    • Hausenloy DJ, Wynne A, Mocanu MM, Yellon DM (2007). The metabolic syndrome raises the threshold for cardioprotection. doi:10.1016/j.yjmcc.2007.03.566
    • Hausenloy DJ, Mwamure PK, Harris J, MacAllister RJ, Yellon DM (2007). Transient upper arm ischemia reduces myocardial injury in patients undergoing cardiac bypass surgery. doi:10.1016/j.yjmcc.2007.03.555
    • Lim SY, Davidson SM, Hausenloy DJ, Yellon DM (2007). Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovascular Research, 75(3), 530 - 535. doi:10.1016/j.cardiores.2007.04.022
    • Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM (2007). Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing CABG surgery: a randomised controlled trial.. The Lancet, 370(9587), 575 - 579. doi:10.1016/S0140-6736(07)61296-3
    • Hausenloy DJ, Wynne AM, Yellon DM (2007). Ischemic preconditioning targets the reperfusion phase. Basic Research in Cardiology, 102(5), 445 - 452. doi:10.1007/s00395-007-0656-1
    • Sivaraman V, Mudalagiri NR, Di Salvo C, Kolvekar S, Hayward M, Yap J, Keogh B, Hausenloy DJ, Yellon DM (2007). Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Research in Cardiology, 102(5), 453 - 459. doi:10.1007/s00395-007-0664-1
    • Yellon DM, Hausenloy DJ (2007). Myocardial reperfusion injury. New England Journal of Medicine, 357(11), 1121 - 1135.
    • Hausenloy DJ, Scorrano L (2007). Targeting cell death.. Clinical Pharmacology and Therapeutics, 82(4), 370 - 373.

    2006

    • Hausenloy DJ, Mocanu MM, Yellon DM (2006). Is this truly ischemic preconditioning?. Circulation Research, 99(4), - . doi:10.1161/​01.RES.0000240435.97872.00
    • Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2006). Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. The International Journal of Biochemistry and Cell Biology, 38(3), 414 - 419. doi:10.1016/j.biocel.2005.09.017
    • Hausenloy D, Tsang A, Yellon D (2006). Failure to ischaemic postcondition the diabetic heart.
    • Hausenloy DJ, Yellon DM (2006). Survival kinases in ischemic preconditioning and postconditioning.. Cardiovascular Research, 70(2), 240 - 253.
    • Hausenloy D, Yellon D (2006). The survival kinases Akt and Erk 1/2 and the mitochondrial permeability transition pore as a common cardioprotective pathway.
    • Showkathali R, Hausenloy D (2006). Echocardiography and the critically ill patient. Current Anaesthesia and Critical Care, 17(3-4), 237 - 244. doi:10.1016/j.cacc.2006.05.002
    • Hausenloy DJ, Tsang A, Yellon DM (2006). Postconditioning does not protect the diabetic heart. doi:10.1016/j.yjmcc.2006.03.119

    2005

    • Hausenloy DJ, Yellon DM (2005). The mitochondrial permeability transition pore as a critical determinant of cell death.
    • Hausenloy DJ, Yellon DM (2005). Protecting the heart at the time of reperfusion: The role of insulin and glucagon-like peptide-1. In (Ed.), (pp. - ). : University of Cape Town Press.
    • Hausenloy DJ, Tsang A, Yellon DM (2005). The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning.. Trends in Cardiovascular Medicine, 15(2), 69 - 75.
    • Yellon DM, Hausenloy DJ (2005). Realizing the clinical potential of ischemic preconditioning and postconditioning.. Nature Clinical Practice Cardiovascular Medicine, 2(11), 568 - 575.
    • Hausenloy DJ, Yellon DM (2005). Protecting the myocardium at time of reperfusion-Meeting report of the Hatter Institute 4th International Workshop on Cardio-protection. Basic Research in Cardiology, 100(4), 383 - 386.
    • D'Souza SP, Hausenloy DJ (2005). Cardiovascular assessment for noncardiac surgery. Current Anaesthesia and Critical Care, 16(4), 263 - 269. doi:10.1016/j.cacc.2005.09.001
    • Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 288(2 57-2), - . doi:10.1152/ajpheart.00374.2004
    • Shanmuganathan S, Hausenloy DJ, Yellon DM, Duchen MR (2005). Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. American Journal of Physiology - Heart and Circulatory Physiology, 289(1 58-1), - . doi:10.1152/ajpheart.01192.2004
    • Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM (2005). Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes, 54(8), 2360 - 2364.
    • Yellon DM, Tsang A, Hausenloy DJ (2005). Myocardial postconditioning: Reperfusion injury revisited. American Journal of Physiology - Heart and Circulatory Physiology, 289(1 58-1), - . doi:10.1152/ajpheart.00091.2005

    2004

    • Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004). Postconditioning - A form of "modified reperfusion" protects the myocardium by activating the PI3K-Akt pathway.
    • Davidson SM, Hausenloy D, Duchen MR, Yellon DM (2004). Insulin inhibits opening of the mitochondrial permeability transition pore via the reperfusion injury salvage kinase (RISK) pathway.
    • Hausenloy D, Wynne A, Yellon DM, Duchen M (2004). Does the mitochondrial permeability transition have a role in preconditioning? Response.
    • Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004). Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway.. Circulation Research, 95(3), 230 - 232. doi:10.1161/01.RES.0000138303.76488.fe
    • Hausenloy D, Mocanu M, Yellon D (2004). Cross-talk between the survival kinases during early reperfusion: its contribution to ischaemic preconditioning.. Cardiovascular Research, 63(2), 305 - 312. doi:10.1016/j.cardiores.2004.04.011
    • Hausenloy DJ, Yellon DM (2004). The importance of the reperfusion phase in ischaemic preconditioning.
    • Hausenloy D, Wynne A, Duchen M, Yellon D (2004). Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection.. Circulation, 109(14), 1714 - 1717. doi:10.1161/01.CIR.0000126294.81407.7D
    • Hausenloy DJ, Yellon DM (2004). New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway.. Cardiovascular Research, 61(3), 448 - 460.
    • Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR (2004). Preconditioning protects by inhibiting the mitochondrial permeability transition. American Journal of Physiology - Heart and Circulatory Physiology, 287(2 56-2), - . doi:10.1152/ajpheart.00678.2003
    • Hausenloy DJ, Yellon DM (2004). Adenosine-induced second window of protection is mediated by inhibition of mitochondrial permeability transition pore opening at the time of reperfusion.. Cardiovascular Drugs and Therapy, 18(1), 79 - 80.
    • Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM (2004). Inhibiting mitochondrial permeability transition pore opening protects the human myocardium from ischemia-reperfusion injury.

    2003

    • Hausenloy DJ, Mocanu MM, Yellon DM (2003). Activation of the pro-survival kinases (PI3 kinase-Akt and Erk 1/2) at reperfusion is essential for preconditioning-induced protection.
    • Hausenloy DJ, Wynne AM, Duchen MR, Yellon DM (2003). Transient mitochondrial permeability transition pore opening mediates ischemic preconditioning-induced protection.
    • Hausenloy DJ, Yellon DM (2003). The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. Journal of Molecular and Cellular Cardiology, 35(4), 339 - 341.
    • Hausenloy D, Duchen MR, Yellon DM (2003). Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.. Cardiovascular Research, 60(3), 617 - 625. doi:10.1016/j.cardiores.2003.09.025

    2002

    • Yellon DM, Hausenloy D (2002). Fish oils and cardioprotection - Mechanisms explored. British Journal of Cardiology, 9(10), 609 - 610.
    • Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002). Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning?.
    • Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002). Inhibiting mitochondrial permeability transition pore opening: A new paradigm in myocardial preconditioning?.
    • Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM (2002). Ischemic preconditioning and mitochondrial K-ATP channel activation protect the myocardium by inhibiting mitochondrial permeability transition pore opening.
    • Hausenloy DJ, Mani-Babu S, Duchen MR, Yellon DM (2002). Mitochondrial KATP channel activation protects the myocyte against oxidative stress by inhibiting mitochondrial permeability transition pore opening.
    • Hausenloy D, Maddock HL, Baxter GF, Yellon DM (2002). Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. Cardiovascular Research, 55(3), 534 - 543. doi:10.1016/S0008-6363(02)00455-8

    1994

    • KIRKMAN E, SHIOZAKI T, HAUSENLOY DJ, LITTLE RA (1994). EFFECTS OF BICUCULLINE ON THE CARDIOVASCULAR-RESPONSE TO HEMORRHAGE AND ITS MODIFICATION BY HINDLIMB ISCHEMIA IN THE ANESTHETIZED RAT.

    • Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence D, Bognolo J, Yellon DM (). Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold blood cardioplegia: a randomised controlled trial. Heart, , - .
    • Hausenloy DJ, Gorog D, Marber M (). Cardiovascular Disease. In (Ed.), (pp. - ). : Cambridge University Press.